BNTX Jan 2024 380.000 call
| Previous close | 45.59 |
| Open | 88.86 |
| Bid | 61.10 |
| Ask | 69.90 |
| Strike | 380.00 |
| Expiry date | 2024-01-19 |
| Day's range | 45.59 - 45.59 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
- Globe Newswire
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included €20M upfront payment, €20M equity investment in Ryvu, research funding, and downstream milestones and royalties;Successfully completed a Public Offering, raising gross proceeds of $56M;Planning to advance RVU120 to Phase II in the treatment of solid tumors and AML/HR-MDS in 2Q and 2H 2023 respectively; clinical updates at upcoming major medical meetings;Pr
- Simply Wall St.
BioNTech SE's (NASDAQ:BNTX) largest shareholders are private equity firms with 43% ownership, individual investors own 20%
Key Insights The considerable ownership by private equity firms in BioNTech indicates that they collectively have a...
- Yahoo Finance
Moderna CEO faces Sen. Sanders in COVID-19 vaccine pricing hearing Wednesday
Moderna CEO Stéphane Bancel is set to face Sen. Bernie Sanders to defend the company's fast growth and planned price hike of its COVID-19 vaccine.
